Современные тенденции в скрининге и дифференциальной диагностике эпителиальных опухолей яичников

1. Management of Suspected Ovarian Masses in Premenopausal Women (Green-top Guideline N 62)
2. Graham L. ACOG Releases Guidelines on Management of Adnexal Masses. Am Fam Physician. 2008; 77(9): 1320-3.
3. Гаспаров А.С., Жорданиа К.И., Паяниди Ю.Г., Дубинская Е.Д. Онкогинекологические аспекты кистозных образований яичников. Вестник Российской академии медицинских наук. 2013; 8 (68): 9-13.
4. Walker J., Powell B., Chen L., et al. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer. 2015; 121: 2108-2120.
5. Webb P., Green A., Jordan S. Trends in hormone use and ovarian cancer incidence in US white and Australian women: implications for the future. Cancer Causes Control. 2017; 28: 365-370.
6. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: ovarian cancer. Available at: https://seer.cancer.gov/statfacts/ html/ovary.html. (Accessed 30 December 2018).
7. Jayson G.C., Kohn E.C., Kitchener H.C., Ledermann J.A. Ovarian cancer. Lancet. 2014; 384: 1376-1388.
8. Chien J., Poole E. Ovarian cancer prevention, screening and early detection: report from the 11th Biennial Ovarian Cancer Research Symposium. Int J Gynecol Cancer. 2018; 27: S20-S22.
9. Institute of Medicine, Committee on the State of the Science in Ovarian Cancer Research, Board on Health Care Services, et al. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington (DC): National Academies Press (US); 2016. PMID: 27253000.
10. Permuth-Wey J., Besharat A., Sellers T. Epidemiology of ovarian cancer: An update. In: Advances in diagnosis and management of ovarian cancer. Farghaly S.A., ed. New York: Springer Science and Business Media; 2014. PMID: None.
11. Wentzensen N., Poole E.M., Trabert B., et al. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016; 34(24): 2888-98. PMID: 27325851. http://dx.doi.org/10.1200/JCO.2016.66.8178
12. Song H., Ramus S.J., Tyrer J., et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet. 2009; 41(9): 996-1000. PMID: 19648919. http://dx.doi.org/10.1038/ng.424
13. Pharoah P.D., Tsai Y.Y., Ramus S.J., et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 2013; 45(4): 362-70, 70e1-2. PMID: 23535730. http://dx.doi.org/10.1038/ng.2564
14. Permuth-Wey J., Lawrenson K., Shen H.C., et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun. 2013; 4: 1627. PMID: 23535648. http://dx.doi.org/10.1038/ncomms2613
15. Kuchenbaecker K.B., Ramus S.J., Tyrer J., et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015; 47(2): 164-71. PMID: 25581431. http://dx.doi.org/10.1038/ng.3185
16. Bolton K.L., Tyrer J., Song H., et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010; 42(10): 880-4. PMID: 20852633. http://dx.doi.org/10.1038/ng.666
17. Bojesen S.E., Pooley K.A., Johnatty S.E., et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013; 45(4): 371-84, 84e1-2. PMID: 23535731. http://dx.doi.org/10.1038/ng.2566
18. National Institute for Health and Care Excellence (NICE). Clinical guideline
19. Daly M.B., Pilarski R., Axilbund J.E., et al. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. J Natl Compr Canc Netw. 2016;14(2):153-62. PMID: 26850485. http://dx.doi.org/10.6004/jnccn.2016.0018
20. Moyer V.A. Force USPST. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 160(4): 271-81. PMID: 24366376. http://dx.doi.org/10.7326/M13-2747
21. Domchek S.M., Friebel T.M., Singer C.F., et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010; 304(9): 967-75. PMID: 20810374. http://dx.doi.org/10.1001/jama.2010.1237
22. Moyer V.A. U.S. Preventive Services Task Force. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2012; 157(12): 900-4.
23. Ledermann J.A., Raja F.A., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Onco. 2013; 24(Suppl 6): vi24-vi32. doi: 10.1093/annonc/mdt333.
24. https://gyn-endo.ru/wp-content/ uploads/2012/08/info20.pdf
25. Lycke M., Kristjansdottir B., Sundfeldt K. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018; 151(1): 159-165. doi:10.1016/j.ygyno.2018.08.025
26. Pinsky P.F., Yu K., Kramer B.S., et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. Gynecol Oncol. 2016; 143(2): 270-5.
27. Jacobs I.J., Menon U., Ryan A., et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016; 387(10022): 945-56.PMID: 26707054.
28. Felder M., Kapur A., Gonzalez-Bosquet J., Horibata S., Heintz J., Albrecht R., Fass L., Kaur J., Hu K., Shojaei H., Whelan R.J., Patankar M.S. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014; 13: 129.
29. Trabert B., Pinto L., Hartge P., Kemp T., Black A., Sherman M.E., Brinton L.A., Pfeiffer R.M., Shiels M.S., Chaturvedi A.K., Hildesheim A., Wentzensen N. Pre-diagnostic serum levels of inflammation markers and risk of ovar- ian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Gynecol Oncol. 2014; 135: 297-304.
30. Boylan K.L.M., Geschwind K., Koopmeiners J.S., Geller M.A., Starr T.K., Skubitz A.P.N. A multiplex platform for the identification of ovarian cancer biomarkers. Clin Proteomics. 2017 Oct 10; 14: 34. doi: 10.1186/s12014-017-9169-6. eCollection 2017.
31. Zhang Z., Chan D.W. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev. 2010; 19(12): 2995-9.
32. Ueland F.R., Desimone C.P., Seamon L.G., et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol. 2011; 117(6): 1289-1297.
33. Kaaks R., Fortner R.T., Husing A., et al. Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. Int J Cancer 2018; 143(3): 515-26.
34. Fortner R.T., Damms-Machado A., Kaaks R. Systematic review: tumor-associated antigen autoantibodies and ovarian cancer early detection. Gynecol Oncol 2017; 147(2): 465-80.
35. Giannopoulou L., Kasimir-Bauer S., Lianidou E.S. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA. Clin Chem Lab Med. 2018; 56: 186-97.
36. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008; 110: 13-21. https:// doi.org/10.1016/j.ygyno.2008.04.033.
37. Yokoi A., Yoshioka Y., Hirakawa A., Yamamoto Y., Ishikawa M., Ikeda S., et al. A combination of circulating miRNAs for the early detection of ovarian cancer. Oncotarget. 2017; 8: 89811-23.
38. Kyriazi S., Kaye S.B., deSouza N.M. Imaging ovarian cancer and peritoneal metastases – current and emerging techniques. Nat Rev Clin Oncol. 2010; 7(7): 381-93. doi: 10.1038/nrclinonc.2010.47.
39. Iyer VR, Lee S. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. American Journal of Roentgenology. 2010; 194: 311-21. doi: 10.2214/AJR.09.3522.
40. Timmerman D., Ameye L., Fischerova D., et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ. 2010;341: c6839.
41. Anthoulakis C., Nikoloudis N., Pelvic MRI. as the ‘‘gold standard’’ in the subsequent evaluation of ultrasound- indeterminate adnexal lesions: a systematic review. Gynecol Oncol. 2014; 132: 661-8.
42. MacKintosh M.L., Rahim R., Rajashanker B., et al. CT scan does not predict optimal debulking in stage III–IV epi- thelial ovarian cancer: a multicentre validation study. J Obstet Gynaecol. 2014; 34(5): 424-8. doi: 10.3109/ 01443615.2014.899330.
43. Solopova A.E., Makatsaria A.D., Sdvizhkov A.M., Ternovoy S.K. Magnetic resonance imaging in the differential diagnosis of ovarian masses: Capabilities of quantitative multiparametric evaluation. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; 2: 80-5. (in Russian) http://dx.doi.org/10.18565/aig.2017.2.80-5
44. Pereira P.N., Sarian L.O., Yoshida A., et al. Accuracy of the ADNEX MR scoring system based on a simplified MRI protocol for the assessment of adnexal masses. Diagn Interv Radiol 2018; 24: 63-71.
45. Morton R., Anderson L., Carter J., et al. Intraoperative frozen section of ovarian tumors: a 6-year review of performance and potential pitfalls in an Australian Tertiary Referral Center. Int J Gynecol Cancer. 2017; 27: 17-21. doi:10.1097/IGC.0000000000000851

Поступила 18.06.2019

Принята в печать 21.06.2019